KRAS Codon 12 Mutations and Detection
By Wei Liu, Ph.D.
/ August 22, 2019
Next-generation sequencing (NGS) is a powerful tool that has seen a fast increase in clinical labs although only a few NGS tests have been approved by the FDA. However, there have been a lot of debate on if variants from NGS sequencing should be confirmed either by Sanger sequencing, the gold standard, or other techniques such as quantitative PCR, or the combination, or other methods.
Read More
HPV-driven Cancers and Somatic Mutations in These Cancers
By Wei Liu, Ph.D.
/ April 18, 2019
Next-generation sequencing (NGS) is a powerful tool that has seen a fast increase in clinical labs although only a few NGS tests have been approved by the FDA. However, there have been a lot of debate on if variants from NGS sequencing should be confirmed either by Sanger sequencing, the gold standard, or other techniques such as quantitative PCR, or the combination, or other methods.
Read More
cfDNA Quantitation for Research and Clinical Applications
By Wei Liu, Ph.D.
/ January 31, 2019
Next-generation sequencing (NGS) is a powerful tool that has seen a fast increase in clinical labs although only a few NGS tests have been approved by the FDA. However, there have been a lot of debate on if variants from NGS sequencing should be confirmed either by Sanger sequencing, the gold standard, or other techniques such as quantitative PCR, or the combination, or other methods.
Read More
Confirmation of NGS for False-negative Variants Using XNA Technology
By Wei Liu, Ph.D.
/ November 15, 2018
Next-generation sequencing (NGS) is a powerful tool that has seen a fast increase in clinical labs although only a few NGS tests have been approved by the FDA. However, there have been a lot of debate on if variants from NGS sequencing should be confirmed either by Sanger sequencing, the gold standard, or other techniques such as quantitative PCR, or the combination, or other methods.
Read More
XNA Molecular Clamps Help Identify False-positive T790M Mutation
By Wei Liu, Ph.D.
/ October 9, 2018
Eighty five percent of the lung cancer patients are non-small cell lung cancer (NSCLC) patients. Among this population, patients with exon 19 deletion and L858R mutations respond well to the first (such as erlotinib and gefitinib) and second generation (such as afatinib and dacomitinib) of tyrosine kinase inhibitors (TKIs). However, all the respondents develop resistance after 9 to 14-month period and more than 50% of the resistance cases are due to the single point mutation at exon 20, T790M.
Read More
Cancer Diagnostics: Targeted Gene Panels for Next Generation of Sequencing
By Wei Liu, Ph.D.
/ September 11, 2018
Need Help?
